1/ Scientists everywhere are looking for countermeasures against #COVID19. @DCVC and @DCVCBio are proud to work with companies like @AbCelleraBio that are making concrete progress.
2/ Moving quickly is key. @AbCelleraBio mapped 500 unique fully human antibody sequences in just 11 days – it’s the largest panel yet and a massive opportunity to identify antibodies that neutralize SARS-COV-2
3/ Together, @AbCellera and @LillyPad will screen these 500 antibodies and test new therapies in patients within the next four months. Not years, but months to a potential countermeasure to stop the outbreak.
4/ @AbCelleraBio screened >5M immune cells, tested and signed this agreement just 11 days after receiving a COVID-19 blood sample through the @DARPA P3 program.
5/ The speed and efficiency of this response is unprecedented and shows how we can all benefit by applying #DeepTech to real-world, global challenges
6/ "We've never moved at this speed before. I'm not sure any company ever has, but I think if there's one situation that demands speed and demands extraordinary effort, it's the COVID-19 pandemic." - @LillyPad CSO Dan Skovronsky businessinsider.com/eli-lilly-abce…
